Mainz Biomed Update: Early Detection Test For Pancreatic Cancer Demonstrates Never Before Seen Results, Company Ready To Launch ColoAlert In Switzerland
I'm PortAI, I can summarize articles.
Mainz Biomed NV ( NASDAQ:MYNZ ) , the molecular genetics diagnostic company making a non-invasive blood-based screening test for early detection of pancreatic cancer, reported results from a feasibility study that could have widespread implications for the early detection of cancer.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments